{"title":"Fatal Tracheal and Bronchial Destruction Due to Pulmonary Mucormycosis in a 20-Year-Old with Diabetic Ketoacidosis.","authors":"Qian He, Xu Huang","doi":"10.2147/IDR.S493002","DOIUrl":null,"url":null,"abstract":"<p><p>Pulmonary mucormycosis is a rare and aggressive invasive fungal infection that predominantly affects immunocompromised individuals, such as those with diabetes mellitus or those undergoing immunosuppressive therapy. This case describes a severe instance of pulmonary mucormycosis resulting in progressive tracheal wall destruction in a young, previously healthy male. A 20-year-old male with a denied history of diabetes mellitus was admitted to a local hospital with abdominal pain for 9 days and diagnosed with acute pancreatitis and diabetic ketoacidosis (DKA). During his stay at the local hospital the patient developed respiratory distress and was transferred to our hospital. Although initially given non-invasive respiratory support and broad-spectrum antibiotics, the patient's condition deteriorated and invasive mechanical ventilation and VV-ECMO were given. Bronchoalveolar lavage fluid (BALF) next-generation sequencing (mNGS) identified Rhizopus species, confirming pulmonary mucormycosis. Aggressive antifungal therapy with amphotericin B was administered, followed by the addition of isavuconazole, but the patient's lesions continued to expand, ultimately leading to fatal tracheal and bronchial wall disruption and subsequent haemorrhage. This case emphasizes the rapid progression and extensive tissue destruction characteristics of pulmonary mucormycosis. Early diagnosis and treatment, especially simultaneous antifungal therapy and appropriate surgical intervention, are crucial for improving the prognosis of such severe cases.</p>","PeriodicalId":13577,"journal":{"name":"Infection and Drug Resistance","volume":"17 ","pages":"5429-5437"},"PeriodicalIF":2.9000,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11634791/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infection and Drug Resistance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/IDR.S493002","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Pulmonary mucormycosis is a rare and aggressive invasive fungal infection that predominantly affects immunocompromised individuals, such as those with diabetes mellitus or those undergoing immunosuppressive therapy. This case describes a severe instance of pulmonary mucormycosis resulting in progressive tracheal wall destruction in a young, previously healthy male. A 20-year-old male with a denied history of diabetes mellitus was admitted to a local hospital with abdominal pain for 9 days and diagnosed with acute pancreatitis and diabetic ketoacidosis (DKA). During his stay at the local hospital the patient developed respiratory distress and was transferred to our hospital. Although initially given non-invasive respiratory support and broad-spectrum antibiotics, the patient's condition deteriorated and invasive mechanical ventilation and VV-ECMO were given. Bronchoalveolar lavage fluid (BALF) next-generation sequencing (mNGS) identified Rhizopus species, confirming pulmonary mucormycosis. Aggressive antifungal therapy with amphotericin B was administered, followed by the addition of isavuconazole, but the patient's lesions continued to expand, ultimately leading to fatal tracheal and bronchial wall disruption and subsequent haemorrhage. This case emphasizes the rapid progression and extensive tissue destruction characteristics of pulmonary mucormycosis. Early diagnosis and treatment, especially simultaneous antifungal therapy and appropriate surgical intervention, are crucial for improving the prognosis of such severe cases.
期刊介绍:
About Journal
Editors
Peer Reviewers
Articles
Article Publishing Charges
Aims and Scope
Call For Papers
ISSN: 1178-6973
Editor-in-Chief: Professor Suresh Antony
An international, peer-reviewed, open access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventative strategies to minimize the development and spread of resistance.